Vivos Inc (OTCMKTS: RDGL) has been climbing up the chart stringing solid trading days together now for the last five days – up over 160%. The company makes a gel that has successfully treated cancerous tumors in both cats and dogs, and now RDGL is looking to make a commercial push.
After the company saw recent positive results at a test at the University of Missouri – Columbia, RDGL released positive statements about moving toward the commercialization of their proprietary product. The test itself saw a canine receive a significant dose of radiation to the suffering animal. Mike Korenko of RDGL added this statement after the test:” We believe that this treatment represents a major step toward commercialization of IsoPet for animal therapy. We designed this test series with a dual purpose as part of the testing that the FDA requires before we begin clinical trials for treating cancer in humans. The success of this test is an important milestone in that process.”
We anticipate treating another five or more canine subjects in the current test series. With this continuing series of treatments, we will further refine our product labeling and the training that will be provided to veterinarians that want to use our product in the future.
Vivos Inc (OTCMKTS: RDGL) is a therapeutic company with a Yttrium-90 based brachytherapy for the treatment of tumors in animals, as alluded to above.
RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.
RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.
Find out when $RDGL reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
The procedure demonstrated the ability to non-surgically place yttrium-90 uniformly in the tumor without significant exposure to normal tissue, a key advantage over conventional external beam therapy.
On the sales side of this innovative gel, RDGL has met with the FDA and the company also brought in third-party help – IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing.
Vivos Inc (OTCMKTS: RDGL) has a market cap of $1.28M and 80.9M shares out. RDGL is seeing ten-day volume over 2M and this could be a stock to watch as more announcements are seemingly on the horizon. We will be writing updates as more news colors out. Sign-up for continuing coverage on shares of $RDGL stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $RDGL, either long or short, and we have not been compensated for this article.